PKP2 and cardiomyopathy: As shown earlier in Fig. 6, a single dose of AAV9:mPkp2 treatment at 1E14 vg/kg after overt cardiomyopathy halted disease progression via reversed adverse right ventricular remodeling, improved LV function, a trending reduction in arrhythmias, and extended median lifespan by ≥ 50 weeks post induction of Pkp2 deletion.